

K013390

5/23/02

510(k) Summary

SUBMITTED BY

FRANCIS X. HURSEY
PRESIDENT

ON SITE GAS SYSTEMS, INC.
35 BUDNEY ROAD
NEWINGTON, CT 06111
860.667.8888

PREPARED:
OCTOBER 10, 2001

REVISED:
May 29, 2002

4-1 Revised 05/29/02

510(k) Summary

Trade Name	QuikClot
Device Class	Class I
Classification Panel Common Name	General and Plastic Surgery Traumatic Wound Dressing
Predicate Device	RDH Bandage, 510(K) Number-K002550
Submitted By	Francis X. Hursey, President
Company Name	On Site Gas Systems
Company Address	35 Budney Road Newington, CT 06111
Company Phone #	860.667.8888
Prepared	October 10, 2001
Revised	May 29, 2002

Device Description

QuikClot is a bulk granular hemostatic agent, which is placed on or into a moderate to severe wound to effect adsorption, and coagulation of same.

QuikClot is intended for emergency use as an external temporary traumatic wound treatment to achieve hemostasis and prevent blood loss.

The effect of QuikClot is purely physical, not chemical in nature. QuikClot has an unusually high adsorptive effect on liquid. This rapid adsorption of water as a blood component serves to concentrate platelets, and increase the speed and effect of their clotting capabilities. This rapid adsorption also diminishes the volume of the liquid present in the wound as a sponge effect, to facilitate clotting.

The product is designed and packaged to be easily packed, carried and applied using only one hand. It is well suited for moderate to large eviscerating wounds, to create hemostasis by coagulation.

Used in conjunction with a sterile bandage and pressurizing wrap, QuikClot will reduce blood loss dramatically, and significantly increase survivability of high-volume catastrophic wounds.

QuikClot has been tested in-house at On Site, at Hartford Hospital, by Johnson & Johnson, and at the University of Connecticut by Micro Test Laboratories, and at USUHS for the military. Testing and results are enclosed.

In Vitro and In Vivo testing on rats, rabbits and larger mammals at the University of Connecticut, QuikClot consistently performed well above Avitene in rate of coagulation and reduction of bleeding time.

Tests of QuikClot by the UConn Chemistry Department showed a lower toxicity score of rat histopathology following application of compound to stop bleeding than other hemostatic agents. Toxicity was only 10% higher than the inert control device used.

Tests by the Chief of Surgery at VAMC, Newington, CT, conducted at Hartford Hospital on rats and pigs' livers and skin, found QuikClot was superior to other hemostatic agents in its ability to stop bleeding.

During March 2002, testing on large mammals was completed. USUHS and the Office of Naval Research developed a large animal model of lethal uncontrolled hemorrhage. This was used to test whether the use of various hemostatic agents (in addition to standard dressing) would decrease bleeding and improve early survival. The study was highly controlled. The following is a brief summary of QuikClot's successful results:

Mortality Rate:	No Dressing = 80%
	Standard Dressing = 33.4%
	Standard Dressing with QuikClot = 0%
Blood Loss	QuikClot = lowest volume of blood loss of tested hemostatic agents.

Biocompatibility testing was completed by ISO 17025 Certified MicroTest Laboratories, Inc., of Agawam, Mass. The tests included:

Test	Sample #	Dated
Agar Overlay Cytotoxicity Test	02-00480	01/29/02
Water Adsorption Rate	02-00254	01/21/02
Skin Sensitization	01-06556	12/21/01
Skin Irritation	01-06555	12/07/01
Intracutaneous Test	01-06554	11/30/01
MEM Elution Cytotoxicity Test	01-06492	11/08/01
Muscle Implant	01-06476	01/08/01

In summary, QuikClot performed extremely well.

QuikClot is a safe, effective, low cost traumatic wound dressing which is substantially alike in purpose, characteristic, process, and result to the RDH bandage, and thereby eligible for approval under 510(k.)



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Mr. C. Burton Gullong
Vice President
On Site Gas Systems, Inc.
100 Production Court
New Britain, CT 06051

MAY 23 2002

Re: K013390
Trade/Device Name: QuikClot
Regulatory Class: Unclassified
Product Code: FRO
Dated: March 27, 2002
Received: March 29, 2002

Dear Mr. Gullong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Mr. C. Burton Gullong

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "Celia M. Witten".

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative
and Neurological Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

STATEMENT OF INDICATIONS FOR USE

QuikClot is intended for emergency use only as an external temporary traumatic wound treatment to achieve hemostasis for moderate to severe bleeding.

for Mark N. Melhem
(Division Sign-Off)

Division of General, Restorative
and Neurological Devices

510(k) Number K013390